Trial Profile

A Phase I clinical study of the safety/tolerability and pharmacokinetics of HZ-H08905 in patients with relapsed or refractory non-Hodgkin's lymphoma

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 17 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs HZH 08905 (Primary)
Indications B-cell lymphoma; Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma; Non-Hodgkin's lymphoma; T-cell lymphoma
Focus Adverse reactions; First in man

Most Recent Events

24 Jan 2024 New trial record
12 Dec 2023 Preliminary Results ( At the data cutoff date of 25 May 2023, n=38) assessing safety and efficacy of HZ-H08905 monotherapy in hematologic malignancies presented at the 65th American Society of Hematology Annual Meeting and Exposition

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com